Form 4: Edgewise Therapeutics CSO Sells Shares After Option Exercise

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, exercised stock options and subsequently sold 100,000 shares of common stock.

Summary

• Alan J. Russell, Chief Scientific Officer and Director of Edgewise Therapeutics, Inc. (EWTX), reported transactions on November 12, 2025.
• Exercised options to acquire 100,000 shares of common stock at an exercise price of $0.18 per share.
• Immediately sold 100,000 shares of common stock at an average price of $21.1245 per share, with prices ranging from $21.00 to $21.35.
• Following these transactions, Russell directly owns 23,400 shares of common stock and 1,147,365 stock options.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (exercise and sell) which is common for executives to manage their compensation and portfolio. While a sale can be seen negatively, it is often part of a pre-planned strategy (Rule 10b5-1) and does not necessarily reflect a negative view of the company's future.

Positives

• The sale price of $21.1245 per share is significantly higher than the exercise price of $0.18 per share, indicating a substantial gain for the insider on these specific shares.

Negatives

• An insider sale, especially by a Chief Scientific Officer, could be interpreted negatively by some investors, suggesting a reduction in personal exposure to the company's stock.

Future Outlook

N/A

Industry Context

This is an insider transaction report, which details a specific executive's stock activity and does not directly provide information on broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal, though it is a common practice for executives to diversify their holdings and manage vested compensation.

Key Dates

Recommendation

The filing details a routine 'exercise and sell' transaction by a key executive, which is common for managing compensation and personal finances. While an insider sale can sometimes be viewed negatively, it does not inherently signal a lack of confidence, especially when part of a pre-arranged plan (as indicated by the 10b5-1 checkbox). The executive still retains a significant number of options. Therefore, a 'hold' recommendation is appropriate as this transaction alone does not provide sufficient new information to alter the fundamental investment thesis for Edgewise Therapeutics.

Keywords

Edgewise Therapeutics, EWTX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Chief Scientific Officer, Alan J. Russell, Biotechnology, Pharmaceuticals